The RAS-RAF-MEK-ERK signaling kinase pathway has been the focus of intense cancer drug development efforts because of its central role in tumor cell proliferation and survival. Although inhibitors of RAF and MEK provide therapeutic validation, tumor resistance challenges their effectiveness. Targeting scaffolding proteins such as IQGAP1 may be a new approach (pages 626–630).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari
References
Flaherty, K.T. et al. N. Engl. J. Med. 363, 809–819 (2010).
Flaherty, K.T. et al. N. Engl. J. Med. 367, 107–114 (2012).
Solit, D.B. & Rosen, N. N. Engl. J. Med. 364, 772–774 (2011).
Flaherty, K.T. et al. N. Engl. J. Med. 367, 1694–1703 (2012).
Ascierto, P.A. et al. Lancet Oncol. 14, 249–256 (2013).
Jänne, P.A. et al. Lancet Oncol. 14, 38–47 (2013).
Jameson, K.L. et al. Nat. Med. 19, 626–630 (2013).
White, C.D., Erdemir, H.H. & Sacks, D.B. Cell Signal. 24, 826–834 (2012).
White, C.D., Brown, M.D. & Sacks, D.B. FEBS Lett. 583, 1817–1824 (2009).
Roy, M., Li, Z. & Sacks, D.B. Mol. Cell Biol. 25, 7940–7952 (2005).
Zhang, J. et al. Nature 463, 501–506 (2010).
Brown, M.D. & Sacks, D.B. Cell Signal. 21, 462–469 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Stuart, D., Sellers, W. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nat Med 19, 538–540 (2013). https://doi.org/10.1038/nm.3195
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3195
